Repository logo
 

The factor inhibiting HIF regulates T cell differentiation and anti-tumour efficacy

Published version
Peer-reviewed

Repository DOI


Type

Article

Change log

Authors

Bargiela, David 
Cunha, Pedro P 
Veliça, Pedro 
Krause, Lena CM 
Brice, Madara 

Abstract

jats:pT cells must adapt to variations in tissue microenvironments; these adaptations include the degree of oxygen availability. The hypoxia-inducible factor (HIF) transcription factors control much of this adaptation, and thus regulate many aspects of T cell activation and function. The HIFs are in turn regulated by oxygen-dependent hydroxylases: both the prolyl hydroxylases (PHDs) which interact with the VHL tumour suppressor and control HIF turnover, and the asparaginyl hydroxylase known as the Factor inhibiting HIF (FIH), which modulates HIF transcriptional activity. To determine the role of this latter factor in T cell function, we generated T cell-specific FIH knockout mice. We found that FIH regulates T cell fate and function in a HIF-dependent manner and show that the effects of FIH activity occur predominantly at physiological oxygen concentrations. T cell-specific loss of FIH boosts T cell cytotoxicity, augments T cell expansion jats:italicin vivo</jats:italic>, and improves anti-tumour immunotherapy in mice. Specifically inhibiting FIH in T cells may therefore represent a promising strategy for cancer immunotherapy.</jats:p>

Description

Keywords

3101 Biochemistry and Cell Biology, 32 Biomedical and Clinical Sciences, 31 Biological Sciences, 3204 Immunology, 3211 Oncology and Carcinogenesis, Cancer, 1.1 Normal biological development and functioning, 1 Underpinning research, Cancer

Journal Title

Frontiers in Immunology

Conference Name

Journal ISSN

1664-3224
1664-3224

Volume Title

15

Publisher

Frontiers Media SA
Sponsorship
Swedish Research Council (2019-01485_VR)
Wellcome Trust (214283/Z/18/Z)